# US 2017/0362246 A1 · Inhibitors of bruton's tyrosine kinase

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0362246 A1
- Document ID: US20170362246A1
- Status: Published application
- Kind: A1
- Application number: 15/692,261
- Filed: 2017-08-31
- Published: 2017-12-21
- Earliest claimed: 2007-03-28
- Assignees: Pharmacyclics, Inc.
- Applicants: Pharmacyclics LLC
- Inventors: Joseph J. Buggy; Wei Chen; Lee Honigberg; David J. Loury; Zhengying Pan; Erik J. Verner
- Web page: https://patentgrep.com/patent/US20170362246A1

## CPC

- C07D 487/04: Ortho-condensed systems
- A61K 31/4985: Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/04: for non-specific disorders of the connective tissue
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 19/10: for osteoporosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 35/04: specific for metastasis
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Described herein are irreversible kinase inhibitor compounds, methods for synthesizing such irreversible inhibitors, and methods for using such irreversible inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate irreversible inhibitor of a protein, including a kinase.

## Claims

### Claim at position 1

1-100. (canceled)

### Claim 101

A compound of Formula (B5) having the structure:
wherein:
Y and R12 taken together form a 4-, 5-, or 6-membered heterocyclic ring;
each Ra is independently H, halogen, CF3, CN, NO2, OH, NH2, -La-(substituted or unsubstituted alkyl), -La-(substituted or unsubstituted alkenyl), -La-(substituted or unsubstituted heteroaryl), or -La-(substituted or unsubstituted aryl), wherein La is a bond, O, S, S(═O), S(═O)2, NH, C(O), CH2, NHC(O)O, NHC(O), or C(O)NH;
G is
wherein R6 is selected from H, lower alkyl or substituted lower alkyl, lower heteroalkyl or substituted lower heteroalkyl, substituted or unsubstituted lower cycloalkyl, and substituted or unsubstituted lower heterocycloalkyl;
or a pharmaceutically acceptable salt thereof.

### Claim 102 (depends on 101)

The compound of claim 101, wherein R6 is selected from lower alkyl or substituted lower alkyl, lower heteroalkyl or substituted lower heteroalkyl, substituted or unsubstituted lower cycloalkyl, and substituted or unsubstituted lower heterocycloalkyl.

### Claim 103 (depends on 102)

The compound of claim 102, wherein R6 is lower alkyl.

### Claim 104 (depends on 103)

The compound of claim 103, wherein R6 is methyl.

### Claim 105 (depends on 101)

The compound of claim 101, wherein Y and R12 taken together form a 5-membered heterocyclic ring.

### Claim 106 (depends on 105)

The compound of claim 105, wherein R6 is selected from lower alkyl or substituted lower alkyl, lower heteroalkyl or substituted lower heteroalkyl, substituted or unsubstituted lower cycloalkyl, and substituted or unsubstituted lower heterocycloalkyl.

### Claim 107 (depends on 106)

The compound of claim 106, wherein R6 is lower alkyl.

### Claim 108 (depends on 107)

The compound of claim 107, wherein R6 is methyl.

### Claim 109

A compound of Formula (B5) having the structure:
wherein:
Y and R12 taken together form a 4-, 5-, or 6-membered heterocyclic ring;
Ra at positions 2, 3, 5, and 6 are each H;
Ra at position 4 is H, halogen, CF3, CN, NO2, OH, NH2, -La-(substituted or unsubstituted alkyl), -La-(substituted or unsubstituted alkenyl), -La-(substituted or unsubstituted heteroaryl), or -La-(substituted or unsubstituted aryl), wherein La is a bond, O, S, S(═O), S(═O)2, NH, C(O), CH2, NHC(O)O, NHC(O), or C(O)NH;
G is
wherein R6 is selected from H, lower alkyl or substituted lower alkyl, lower heteroalkyl or substituted lower heteroalkyl, substituted or unsubstituted lower cycloalkyl, and substituted or unsubstituted lower heterocycloalkyl;
or a pharmaceutically acceptable salt thereof.

### Claim 110 (depends on 109)

The compound of claim 109, wherein Ra at position 4 is -La-(substituted or unsubstituted heteroaryl).

### Claim 111 (depends on 110)

The compound of claim 110, wherein La is C(O)NH.

### Claim 112 (depends on 111)

The compound of claim 111, wherein Y and R12 taken together form a 5-membered heterocyclic ring.

### Claim 113 (depends on 112)

The compound of claim 112, wherein R6 is selected from lower alkyl or substituted lower alkyl, lower heteroalkyl or substituted lower heteroalkyl, substituted or unsubstituted lower cycloalkyl, and substituted or unsubstituted lower heterocycloalkyl.

### Claim 114 (depends on 113)

The compound of claim 113, wherein R6 is lower alkyl.

### Claim 115 (depends on 114)

The compound of claim 114, wherein R6 is methyl.

### Claim 116 (depends on 109)

The compound of claim 109, wherein Y and R12 taken together form a 5-membered heterocyclic ring.

### Claim 117 (depends on 116)

The compound of claim 116, wherein R6 is selected from lower alkyl or substituted lower alkyl, lower heteroalkyl or substituted lower heteroalkyl, substituted or unsubstituted lower cycloalkyl, and substituted or unsubstituted lower heterocycloalkyl.

### Claim 118 (depends on 117)

The compound of claim 117, wherein R6 is lower alkyl.

### Claim 119 (depends on 118)

The compound of claim 118, wherein R6 is methyl.

### Claim 120

A compound of Formula (B5) having the structure:
wherein:
Y and R12 taken together form a 4-, 5-, or 6-membered heterocyclic ring;
each Ra is independently H, halogen, CF3, CN, NO2, OH, NH2, -La-(substituted or unsubstituted alkyl), -La-(substituted or unsubstituted alkenyl), -La-(substituted or unsubstituted heteroaryl), or -La-(substituted or unsubstituted aryl), wherein La is a bond, O, S, S(═O), S(═O)2, NH, C(O), CH2, NHC(O)O, NHC(O), or C(O)NH;
G is
wherein R6 is selected from H, lower alkyl or substituted lower alkyl, lower heteroalkyl or substituted lower heteroalkyl, substituted or unsubstituted lower cycloalkyl, and substituted or unsubstituted lower heterocycloalkyl.

### Claim 121 (depends on 120)

The compound of claim 120, wherein R6 is selected from lower alkyl or substituted lower alkyl, lower heteroalkyl or substituted lower heteroalkyl, substituted or unsubstituted lower cycloalkyl, and substituted or unsubstituted lower heterocycloalkyl.

### Claim 122 (depends on 121)

The compound of claim 121, wherein R6 is lower alkyl.

### Claim 123 (depends on 122)

The compound of claim 122, wherein R6 is methyl.

### Claim 124 (depends on 120)

The compound of claim 120, wherein Y and R12 taken together form a 5-membered heterocyclic ring.

### Claim 125 (depends on 124)

The compound of claim 124, wherein R6 is selected from lower alkyl or substituted lower alkyl, lower heteroalkyl or substituted lower heteroalkyl, substituted or unsubstituted lower cycloalkyl, and substituted or unsubstituted lower heterocycloalkyl.

### Claim 126 (depends on 125)

The compound of claim 125, wherein R6 is lower alkyl.

### Claim 127 (depends on 126)

The compound of claim 126, wherein R6 is methyl.
